12:01 AM EDT, 09/30/2026 (MT Newswires) -- DBV Technologies (DBV.PA) filed a biologics license application with the US Food and Drug Administration for use of the Viaskin Peanut Patch food allergy treatment in children aged four to seven years. The late-stage biopharmaceutical company said Tuesday that it requested priority review from the regulator for the application, noting that the FDA previously issued Breakthrough Therapy Designation for the peanut patch.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.